\square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	urden								

hours per response:	0.5
Estimated average burde	n

1. Name and Address of Reporting Person* Arbuckle Stuart A			2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]		tionship of Reporting Perso all applicable) Director Officer (give title below)	n(s) to Issuer 10% Owner Other (specify below)	
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED		,	3. Date of Earliest Transaction (Month/Day/Year) 07/13/2018		EVP\Chief Commerci	ial Officer	
50 NORTHERN AVENUE			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	vidual or Joint/Group Filing (Check Applicable		
(Street)	МА	02210		X	Form filed by One Report	Ç.	
	1717 2				Form filed by More than (Person	Jhe Reporting	
(City)	(State)	(Zip)					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Benorted	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code V Amount (A) or (D) Price Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)				
Common Stock	07/13/2018		М		6,375	A	\$131.89	53,127	D	
Common Stock	07/13/2018		S ⁽¹⁾		6,375	D	\$179	46,752	D	
Common Stock	07/16/2018		М		2,125	A	\$96.87	48,877	D	
Common Stock	07/16/2018		S ⁽¹⁾		2,125	D	\$179.85	46,752	D	
Common Stock								140	Ι	401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$131.89	07/13/2018		М			6,375	(2)	07/20/2025	Common Stock	6,375	\$0.00	10,625	D	
Stock Option (Right to Buy)	\$96.87	07/16/2018		М			2,125	(3)	07/14/2024	Common Stock	2,125	\$0.00	0	D	

Explanation of Responses:

1. Transaction made pursuant to Mr. Arbuckle's company-approved trading plan under Rule 10b5-1.

2. The option vests in 16 quarterly installments from 7/21/2015.

3. Fully vested.

Remarks:

/s/ Stephen Migausky,

Attorney-in-Fact

07/17/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.